Project Oncology

Guest: Alison Wakoff Loren, MD, MSCE Cancer occurs in approximately 1 in every 1,000 pregnant patients and requires complex solutions from a multidisciplinary team. Learn more about the expanding management options for these patients with Dr. Alison Loren, Chief of the Division of Hematology and Oncology at the University of Pennsylvania Perelman School of Medicine.

Host: Jacob Sands, MD Guest: Joseph O. Jacobson, MD Over the past few decades, increasing attention has been placed on reducing the risk of patient harm within the healthcare system. Learn more about the risks that are specific to medical oncology and how current systems are addressing them with Dr. Jacob Sands and Dr. Joseph Jacobson, Senior Advisor for Quality and Patient Safety at Dana-Farber Cancer Institute.

Host: Jacob Sands, MD Guest: Aliyah Pabani, MD Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.

Host: Jacob Sands, MD Guest: Biagio Ricciuti, MD Treatment for lung cancer can be complex, but PL-L1 expression and tumor mutational burden might help us select the best treatment for our patients. What do we need to know about the role of these biomarkers in the treatment of lung cancer? To discuss this, Dr. Jacob Sands is joined by Dr. Biagio Ricciuti, a medical oncologist at the Dana-Farber Cancer Institute.

Host: Jacob Sands, MD Guest: Eleni Rettig, MD HPV is the leading cause of oropharynx cancers in the United States, but with no screening tools currently available, how we can detect this cancer in our patients? Host Dr. Jacob Sands speaks with a leader in the field, Dr. Eleni Rettig, an Assistant Professor of Otolaryngology-Head and Neck Surgery at Harvard Medical School, to share risk factors and explore emerging diagnostic tools.

Host: Mario R. Nacinovich, Jr., MSc Guest: Gregory Sepich-Poore, MD/PhD Results from a recent study detail the impact that fungi can have in human cancer tumors. What do we need to know? Mario Nacinovich speaks with one of the researchers, Dr. Gregory Sepich-Poore from UC San Diego, to dive further into these results and their impact on cancer therapeutics.

Host: Pavani Chalasani, MD, MPH Guest: Hope S. Rugo, MD, FASCO Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.

Host: Jacob Sands, MD Guest: Edward B. Garon, MD, MS Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.

Host: Pavani Chalasani, MD, MPH Guest: Prof. David Cameron A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.

Host: Pavani Chalasani, MD, MPH Guest: Erika Hamilton, MD A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Erika Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology.

Host: Pavani Chalasani, MD, MPH Guest: Kevin Kalinsky MD, MS CDK4/6 inhibitors have changed the treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer. But if the disease progresses, should we switch our patients to endocrine therapy? Joining Dr. Pavanai Chalasani to answer this question and share the most recent research from the MAINTAIN trial is lead researcher, Dr. Kevin Kalinsky from the Winship Cancer Institute at Emory University.

Host: Pavani Chalasani, MD, MPH Guest: Nan Chen, MD Immunotherapy is starting to make its way in breast cancer, especially triple-negative breast cancer. So how do we identify which of our patients are good candidates for this treatment? Joining Dr. Pavani Chalasani to share the most recent research on immunotherapy is Dr. Nan Chen, an Assistant Professor of Medicine at the University of Chicago.

Host: Pavani Chalasani, MD, MPH Guest: Seema A. Khan, MD Dr. Pavani Chalasani meets with Dr. Seema Khan, a Professor of Surgery and Interim Co-Vice Chair of Research at Northwestern Feinberg School of Medicine, to explore the role of surgery in metastatic breast cancer and take a look at the current treatment landscape.

Host: Jacob Sands, MD Guest: Maya Leiva, PharmD, BCOP What causes drug shortages in the U.S.? Joining Dr. Jacob Sands to answer this question and dive in to what physicians and pharmacists can do to prepare for future shortages is Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy specialist at Inova Schar Cancer Institute.

Host: Jacob Sands, MD Guest: Maya Leiva, PharmD, BCOP Recognizing bias and improving diversity is critical for patient outcomes, especially within the field of oncology. To explore how we can improve care for both LGBTQ+ patients and employees within healthcare, Dr. Jacob Sands is joined by Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy specialist at Inova Schar Cancer Institute.

Host: Pavani Chalasani, MD, MPH Guest: Kevin Kalinsky MD, MS Chemotherapy is one of the most commonly used treatments for cancer—but it can lead to challenging side effects. So do all of our patients really need it? Joining Dr. Pavani Chalasani to discuss whether or not chemotherapy is the right choice for patients with hormone receptor-positive HER2-negative, node-positive breast cancer is Dr. Kevin Kalinsky from Emory University.

Host: Jacob Sands, MD Guest: Marie Wood, MD Can our breast cancer patients benefit from chemoprevention? Joining Dr. Jacob Sands to share treatment options for chemoprevention and which patients may benefit the most is Dr. Marie Wood, the Director of Breast Medical Oncology and Director of the Cancer Clinical Trials Office at the University of Colorado Anschutz Medical Center.

Host: Pavani Chalasani, MD, MPH Guest: Aditya Bardia, MD, MPH For patients with hormone receptor-positive HER 2-negative metastatic breast, treatment can be challenging. But what treatment options are available? Lead investigator from the EMERALD trial Dr. Aditya Bardia joins Dr. Pavani Chalasani to share his insights.

Host: Pavani Chalasani, MD, MPH Guest: Aditya Bardia, MD, MPH Triple-negative breast cancer can be a challenging battle for patients, especially when it comes to treatment. And that's why the ASCENT trial dove into the treatment landscape for these patients. Lead investigator of this trial, Dr. Aditya Bardia, sits down with Dr. Pavani Chalasani for an inside look at this trial and what it means for patients with triple-negative breast cancer.

Host: Jacob Sands, MD Guest: Manish A. Shah, MD FASCO For patients with unresectable liver-limited hepatocellular carcinoma, treatment can be challenging. Clinicians typically care for these patients with local-regional therapies, but is that the best option for all of them? To answer this question, Dr. Jacob Sands joins Dr. Manish Shah from Weill Cornell Medicine to take a look at current and emerging strategies for managing and treating unresectable liver-limited hepatocellular carcinoma.